Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conservative approach in rectal cancer
ISRCTN60597075Phase 2Completed
- Sponsor
- Regional Health and Social Agency of Emilia-Romagna
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal adenocarcinoma, sponsored by Regional Health and Social Agency of Emilia-Romagna. Primary endpoints: Local recurrence at 2 years and Local recurrence at 5 years. Started Jun 2013; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN60597075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60597075.